The decline of Lecanemab and Donanemab Slow Alzheimer, but is it worth the cost?

New research shows that Lecanemab and Donanemab can slow down cognitive decline and extend patients’ independence to daily activities. But at high costs and risks, are these treatments really important to Alzheimer’s patients and their families?

Study: Assessment of the clinical significance of the deceleration of CDR-SB’s progression with treatments for modification of the disease for Alzheimer’s disease. Credit Picture: Shutterstock Ai Generator / Shutterstock.com

A recent Alzheimer’s and dementia The study explores the effects of treatment at the time when patients with Alzheimer’s disease (AD) spend to remain independent in the basic activities of daily living (BADL) and the organic activities of daily life (IADLS).

Current treatments for advertising

AD is a neurodegenerative disorder characterized by a cerebral accumulation of amyloid and Tau pathology, causing synaptic and neuronal damage leading to progressive dementia. Several therapies, including anti-amyloid monoclonal antibodies, have been developed to reduce cerebral amyloid burden that may delay ad progress.

In July 2023, the United States Food and Drug Administration (FDA) approved Lecanemab as the treatment of disease modification (DMT) to combat early symptomatic AD. Soon, in July 2024, Donanemab was also approved. However, in some cases, both treatments have been associated with minimal clinical importance in slowing dementia.

Both Lecanemab and Donanemab are expensive treatments that can increase the risk of amyloid -related neuroimaging. As a result, some doctors are reluctant to start these treatments, as every treatment must prove clinical importance to offset the potential risks and costs.

Evaluation of the severity of advertising

Clinical Rating Dementia (CDR) It is a global scale used to determine the state of dementia and its severity by measuring the extent of cognitive loss in different areas. These areas include memory, crisis, orientation and problem solving, along with functional skills in community affairs, home and personal care.

Each CDR sector is scored from zero to three, reflects healthy and severely weakened knowledge. The sum of the CDR or “boxes” scores yields the CDR-SUM (CDR-SB), a continuous measure with scores ranging from zero to 18.

Although there is no clear consensus on a “clinically important” benefit to advertising dementia, knowledge and performance of functions must be evaluated to understand the benefits of advertising treatment. The clinical benefits explained in terms of statistical significance do not always help carers or family members understand the results of treatment. As a result, other measurements such as IADL and BADL can be used to quantify functional independence in patients with AD.

For the study

The current study was conducted at the Knight Alzheimer’s (Knightadrc) research center at the University of Washington. Both cognitive and cognitive disorder of Community persons who agreed to undergo amyloid positron (PET) and lumbar perforation (LP) were included in the analysis. All study participants also provided samples of cerebrospinal fluid (CSF) for evaluation of amyloid beta (AB) and TAU protein.

All participants underwent clinical and cognitive evaluations to obtain the CDR rating. Based on standard criteria and a global CDR score, a clinical diagnosis of dementia was identified.

Study findings

This study included 282 participants, 67% of which had a very mild advertising dementia and 33% with mild adena AD, which was scored by one. About 56% of the study group were men, 88% were non -Spanish white and 10% were black or African Americans.

Most CDR 0.5 participants were independent, while only 40% of CDR 1 participants were independent. At the start, almost all participants were independent in Badl.

Four IADL ingredients were considered functions of the CDR-SB score, allowing the level of independence to be estimated. These components included payment bills, driving, memory/appointment and meal preparation.

Based on this approach, about 50% of study participants depends. Some participants could independently prepare their meals and remember an appointment/medicine at a higher CDR-SB rating, but failed to pay bills and drive effectively.

There was a strong relationship between CDR and ADLS. About 93% of CDR-SB participants less than 4.5 were independent in IADLS, while 87% of CDR-SB participants were over 4.5 did not have independence in IADLS.

In addition, 97% of CDR-SB participants less than 11.5 were independent in badls. By comparison, 85% of CDR-SB participants exceeding 11.5 did not show independence in Badl.

The average annual increase in CDR-SB was 1.30. However, when this measurement was shaped as a function of the basic CDR, the CDR-SB increased by 1.05 each year for people with 0.5 CDR and one at the start. Overall, a linear increase in CDR-SB has been observed over time.

The expected time to lose independence in Iadls was about 29 months. Interestingly, the additional years of independence in IADL and Badls were associated with Lecanemab or Donanemab treatments, which could be due to a slower rate of reduction in CDR-SB.

Assuming a steady decrease in CDR-SB rating rate after treatment, an additional 10 and eight months of independence in IADLS were associated with Lecanemab and Donanemab therapies, respectively. For the treatment with Donanemab, an additional 13 months of independence in IADLS for the Pet Low/Medium Tau team was observed, while four months of independence in IADLS were measured for the high Tau Pet.

Conclusions

The current study provides new knowledge of the relationship between CDR-SB ratings and functional independence. These findings also emphasize the clinical significance of ads and if patients and their families can make more up -to -date treatment decisions.